Rivus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company advancing novel medicines for obesity and the resulting chronic cardiometabolic diseases. Our team is developing a new class of oral investigational medicines called Controlled Metabolic Accelerators (CMAs). Our lead candidate HU6 (an ANT-activator) has demonstrated positive results in three Phase 2 clinical trials across MASH (metabolic dysfunction associated steatohepatitis), MASLD (metabolic dysfunction-associated steatotic liver disease), and HFpEF (heart failure with preserved ejection fraction). For more information, please visit www.rivuspharma.com.
Company Details
- Employees
- 27
- Founded
- 2019
- Address
- Charlottesville, Va, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.rivuspharma.com/
- HQ
- Charlottesville, VA
Rivus Pharmaceuticals Questions
Rivus Pharmaceuticals's website is https://www.rivuspharma.com/
Rivus Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/rivus-pharmaceuticals
Rivus Pharmaceuticals has
27 employees.
View email and phone details for 27
employees at Rivus Pharmaceuticals.
Rivus Pharmaceuticals's industry is
Biotechnology Research
Rivus Pharmaceuticals's top competitors are
Emalex Biosciences,
Galecto, Inc.,
Avalyn Pharma,
Aviceda Therapeutics,
Vertex Pharmaceuticals,
Jade Biosciences,
Summit Therapeutics, Inc.,
Arena Pharmaceuticals, Inc.,
Orsobio,
Akero Therapeutics.
Rivus Pharmaceuticals's categories are Biotechnology Research
Rivus Pharmaceuticals's founding year is 2019
